GE

222.74

+0.57%↑

RTX

130.94

+0.06%↑

CAT

349.99

-1.03%↓

BA

204.54

+0.43%↑

HON

216.98

-0.7%↓

GE

222.74

+0.57%↑

RTX

130.94

+0.06%↑

CAT

349.99

-1.03%↓

BA

204.54

+0.43%↑

HON

216.98

-0.7%↓

GE

222.74

+0.57%↑

RTX

130.94

+0.06%↑

CAT

349.99

-1.03%↓

BA

204.54

+0.43%↑

HON

216.98

-0.7%↓

GE

222.74

+0.57%↑

RTX

130.94

+0.06%↑

CAT

349.99

-1.03%↓

BA

204.54

+0.43%↑

HON

216.98

-0.7%↓

GE

222.74

+0.57%↑

RTX

130.94

+0.06%↑

CAT

349.99

-1.03%↓

BA

204.54

+0.43%↑

HON

216.98

-0.7%↓

Search

Ocugen Inc

Closed

0.69

Overview

Share price change

24h

Current

Min

0.68

Max

0.72

Key metrics

By Trading Economics

Income

-1.5M

-15M

Sales

717K

1.5M

EPS

-0.05

Profit margin

-1,036.462

Employees

95

EBITDA

-1.3M

-15M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+804.29% upside

Dividends

By Dow Jones

Next Earnings

7 Aug 2025

Market Stats

By TradingEconomics

Market Cap

28M

204M

Previous open

0.69

Previous close

0.69

Technical Score

By Trading Central

Confidence

Strong Bearish Evidence

Ocugen Inc Chart

Past performance is not a reliable indicator of future results.

Related News

14 May 2025, 23:40 UTC

Hot Stocks

Stocks to Watch: UnitedHealth Group, Foot Locker, CoreWeave

14 May 2025, 23:33 UTC

Major Market Movers

UnitedHealth Group Shares Fall After WSJ Reports of Investigation for Possible Medicare Fraud

14 May 2025, 23:25 UTC

Major Market Movers

Biohaven Shares Down as FDA Extends PDUFA Data for Troriluzole

14 May 2025, 23:25 UTC

Earnings

Xero Lifts Fiscal Year Profit 30% on Higher Prices, Subscriber Growth -- Update

14 May 2025, 22:58 UTC

Earnings

Xero Lifts Fiscal Year Profit 30% on Higher Prices, Subscriber Growth

14 May 2025, 21:35 UTC

Earnings

Cisco Systems Names Patterson as CFO, Patel as President

14 May 2025, 23:59 UTC

Market Talk

Implications of Xero's Cost Outlook Aren't Clear -- Market Talk

14 May 2025, 23:49 UTC

Market Talk

Xero's Cost Outlook Likely to Prompt Downgrades -- Market Talk

14 May 2025, 23:48 UTC

Market Talk

Global Equities Roundup: Market Talk

14 May 2025, 23:48 UTC

Market Talk

Nikkei May Decline on Profit-Taking After Recent Gains -- Market Talk

14 May 2025, 23:47 UTC

Market Talk

Gold Gains on Possible Technical Recovery -- Market Talk

14 May 2025, 23:34 UTC

Acquisitions, Mergers, Takeovers

Agnico-Eagle Mines to Subscribe for 30M Voting Common Shares of Foran Mining in Non-Brokered Private Placement at C$3 a Share

14 May 2025, 23:10 UTC

Earnings

Xero Lifts FY Profit 30% on Higher Prices, Subscriber Growth -- Update

14 May 2025, 23:07 UTC

Earnings

CoreWeave Posts Strong Revenue and Wins Google as a Customer. Stock Still Dives on Outlook. -- Barrons.com

14 May 2025, 23:00 UTC

Top News

UnitedHealth Group Is Under Criminal Investigation for Possible Medicare Fraud -- WSJ

14 May 2025, 22:43 UTC

Earnings

Xero Lifts FY Profit 30% on Higher Prices, Subscriber Growth

14 May 2025, 22:34 UTC

Earnings

Xero Expects 1H Operating Expense Ratio to Be Higher Than 2H>XRO.AU

14 May 2025, 22:33 UTC

Earnings

Xero Expects FY26 Operating Expense Ratio of 71.5%>XRO.AU

14 May 2025, 22:30 UTC

Earnings

Xero Did Not Declare a Dividend>XRO.AU

14 May 2025, 22:30 UTC

Earnings

Xero FY Operating Expenses 71.8% of Operating Revenue Vs. 73.3%>XRO.AU

14 May 2025, 22:30 UTC

Earnings

Xero FY Free Cashflow Margin 24.1% Vs. 20.0%>XRO.AU

14 May 2025, 22:30 UTC

Earnings

Xero FY Free Cashflow NZD506.7M Vs. NZD342.1M>XRO.AU

14 May 2025, 22:28 UTC

Earnings

Xero FY Ebitda NZD638.5M Vs. NZD497.4M>XRO.AU

14 May 2025, 22:28 UTC

Earnings

Xero FY Adjusted Ebitda NZD640.6M Vs. NZD526.5M>XRO.AU

14 May 2025, 22:27 UTC

Earnings

Xero FY Rev NZD2.10B Vs. NZD1.71B >XRO.AU

14 May 2025, 22:27 UTC

Earnings

Xero FY Net NZD227.8M Vs. Net NZD174.6M >XRO.AU

14 May 2025, 22:23 UTC

Top News

Boeing, GE Aerospace Get Qatar Airways Order After Saudi AI Tech Deals -- 2nd Update

14 May 2025, 22:15 UTC

Earnings

Correction to Cisco Earnings Article -- WSJ

14 May 2025, 21:48 UTC

Earnings

CoreWeave Posts Strong Revenue but Stock Dives on Updated Outlook -- Barrons.com

14 May 2025, 21:37 UTC

Earnings

Cisco Reports Solid Earnings. The Stock Is Rising. -- Barrons.com

Peer Comparison

Price change

Ocugen Inc Forecast

Price Target

By TipRanks

804.29% upside

12 Months Forecast

Average 6.33 USD  804.29%

High 8 USD

Low 4 USD

Based on 3 Wall Street analysts offering 12 month price targets forOcugen Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

3 ratings

3

Buy

0

Hold

0

Sell

Technical Score

By Trading Central

0.6818 / 0.74Support & Resistance

Short Term

Strong Bearish Evidence

Intermediate Term

Strong Bullish Evidence

Long Term

No Evidence

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Ocugen Inc

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.